Pharmaceutical company payments to authors of the Japanese Clinical Practice Guidelines for Hepatitis C treatment

Background & Aims Promotional activities of pharmaceutical companies (Pharma) relating to newly marketed direct-acting antivirals (DAAs) may have targeted the authors of the Japanese Clinical Practice Guidelines (CPGs) for Hepatitis C. This study aimed to assess payments made by Pharma to the CPG authors and the financial conflicts of interest (FCOIs) reported by those authors. Methods We analyzed payments reported by Pharma to the CPG authors as well as the COI as published by the JSH, using publicly available data for 2016 and 2017. Results A total of 35 of 78 Pharma-reported payments of $613,973 in 2016, while 40 of 73 Pharma declared payments of $524,674 in 2017, with six companies failing to report. Payments by Pharma manufacturing DAAs accounted for 53.7% of the total (55.7% and 51.6% in 2016 and 2017 respectively). All 17 authors received payments from Pharma which totalled $1,138,647. The mean and median payments per author were $66,979 (standard deviation (SD): $64,875) and $46,033 (interquartile range [IQR]: $29,796 - $34,428) for 2016 and 2017 combined. Conclusions Financial relationship between Pharma and the Hepatitis C CPG authors, which was unclear owing to the guideline regulation, was clarified. The authors had the strongest ties to the Pharma which manufactures DAAs in 2016 and 2017.

Automated summary

This study examined the payments made by pharmaceutical companies to the authors of the Hepatitis C Clinical Practice Guidelines and the financial conflicts of interest reported by the authors. The results showed that all authors received payments from pharmaceutical companies, with a strong relationship to the companies manufacturing DAAs.